

NextGenET




*A Simplified Endotracheal Tube to Prevent
Ventilator-Associated Pneumonia*



Current endotracheal tubes
fail to seal the airway

Ventilator
Associated
Pneumonia



1 in 3

ICU Intubation Patients Contract
Ventilator **A**ssociated **P**neumonia

50%



Average Mortality Rate of VAP



> 300,000

Preventable Deaths Each Year

ISO Testing Results



BACTERIA
ENTERING THE LUNGS

NextGenET

Our Early Stage Differentiation (<1 year)

Customer Discovery

Completed 50+ Interviews with clinical and purchasing experts



Intellectual Property

Provisional patent filed by the University of Pittsburgh



Competitive Differentiation

NextGenET



**Standard
Cuffed ET**



**TaperGuard
Cuffed ET**



**Subglottic
Secretion
Drainage ET**



Marketed to Prevent VAP



Completely Seals Airway



Reduces Monitoring



**Maintains Seal During
Extubation**



Price


\$\$

\$


\$\$

\$\$\$

Market Strategy



Timeline and Milestones



Team



Carl Snyderman, MD, MBA
Principle Investigator
Test Planning



Garrett Coyan, MD, MS
Regulatory Strategy



Ross Beresford, MS
Project Management &
Fundraising



Lauren Grice, BS
Engineering Research & Design



Garrett Craig, BS
Engineering Research & Design